Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...
Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...
The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.
The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...
Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback